Please assess the completion status of the following clinical trial:

Trial Title: INTERVENE: Indian Trial of Endocardial Ventricular Substrate Ablation to Prevent Recurrent VT Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 and ≤ 85 years of age~* History of a remote MI (≥1 month)~* Survival of a ventricular arrhythmic event (VT/VF) that would mandate placement of an implantable cardioverter-defibrillator (ICD) (Patients who experience a ventricular arrhythmic event (VT/VF) while already being treated with Amiodarone (100-200 mg/day) are not excluded from the study. This is permitted provided that the patient had been treated with Amiodarone for at least 2 months prior to experiencing the index VT/VF event. These patients are randomized to either a higher dose of Amiodarone (e.g., 100mg/day -\> 200mg/day or 200mg/day -\> 400mg/day) or a higher dose of Amiodarone plus catheter ablation.)~* Patient cannot afford an ICD and thus has been planned for treatment with Amiodarone (or an increased dose of Amiodarone)~* Ability to understand the requirements of the study~* Willingness to adhere to study restrictions and comply with all post- procedural follow-up requirements~Exclusion Criteria:~* Patients with NYHA class IV congestive heart failure~* Prior ablation for a ventricular arrhythmia~* Presence of an LV thrombus~* Contraindication to anticoagulation~* Inability to access the endocardium because of mechanical mitral and aortic valve~* Life expectance \<1 year for any medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Amiodarone only (Type: ACTIVE_COMPARATOR): The control group will receive amiodarone only.
- Amiodarone + Catheter Ablation (Type: EXPERIMENTAL): The experimental group will receive amiodarone plus catheter VT ablation.

Based on this trial design, predict the completion outcome and termination type (if applicable).